Novo Nordisk flags Wegovy pill weight loss in line with injection
Danish drug producer Novo Nordisk’s logos with flags, box -office diabetes and weight loss treatments Ozempic and Wegovy painting, while the company on February 5, 2025, Bagsvaerd offers an annual report in Novo Nordisk in Denmark.
Mads Claus Rasmussen | AFP | Getty Images
Novo Nordisk In a statement on Wednesday, once a day, the late stage trial results for obesity pills, drug producers competing to get an oral treatment to the market, while breaking box office records in the direction of Wegovy injection showed that “important” weight reduction and tolerability.
Danish Pharmaceutical Company showed that the results of the phase 3 oasis 4 work showed that oral Semaglidid pills are 16.6% in obesity or overweight patients after 64 weeks and at least one weight -related comorbidity.
Martin Holst Lange, Chief Science Officer of Novo Nordisk, called “Wegovy Pill”, said that oral treatment offers an important alternative to patients once a week.
“Our job was to show that we can achieve the same safety and tolerability as the same activity and injected as the injected.” He said.
“This is basically means that we can choose between tablets and injectable patients and make a difference for some patients.”
The oral treatment of Novo Nordisk is based on the same Semaglid GLP-1 drugs that support Wegovy and Özempic for the company’s existing obesity and diabetes treatments. It has been shown that Wegovy reduces an average of 15% in patients with overweight or obesity, and reduces comorbidity associated with at least one weight in an earlier Novo study.
The pill is currently presented with the US Food and Pharmaceutical Administration within the scope of a new drug application in February. A decision is made in the fourth quarter of this year.
If approved, the company said that the pill will be made in the USA, because global pharmaceutical companies have increased US investments due to the pressure of supporting domestic production from Trump administration.
Obesity pill race
Currently, GLP-1s do not have approved oral versions in the market, but competition is rapidly heating. Hill treatments are considered an important milestone for companies that want to make drugs more accessible, including those who avoid needles.
Analysts said Reuters Tuesday This opponent Hand LillyObesity pill Obesity Pill Obesity Pill can be watched quickly for approval within a to two months in accordance with the “national priority coupon of the Commissioner of the FDA-a new attempt to advance the drug development targets of the Trump administration.
Lange said Novo welcomed “good competition”, but focused on drug results, including long -term adoption rates.
“In this case, we’re looking at the data, Lan Lange said. “As a tablet, Semagluid has the potential to present 17% body weight loss and good safety and tolerable profile.”
“What we see from our opponent is slightly more than 12% weight loss. And again, we cannot make direct comparisons, but at least we can see a cutting rate, which is perhaps a semagludidin [more] Effective safety and tolerable profile. “
In a Phase 3 Acaded-1 attempt published on Tuesday, Eli Lilly said that adults with the obesity of Orborglpron resulted in an average of 12.4% at an average of 12.4% or at least one comorbidity after 72 weeks.
However, the US drug producer said on Wednesday that the pill, pill, type of patients with type 2 diabetes in the first -head -headed comparing the effectiveness of the two drugs to reduce blood sugar levels, he said.
Both companies are called a new generation of drugs, novo promises a new form of the treatment treatment in the analogue of the amilin, which has been ongoing for a long time on Tuesday.
Last week, the Danish company announced that it plans to cut approximately 9,000 roles under a wider jolt under a new CEO Mike Dustdar, which promised to reset the company after a weaker growth period.
“What we’re doing right now is to focus on our nucleus, which we’re doing right now. He said.
